Trials / Completed
CompletedNCT01099527
A Trial of RAD001/Capecitabine in Refractory Gastric Cancer
A Phase I/II Trial of RAD001/Capecitabine in Refractory Gastric Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Capecitabine is an oral fluoropyrimidine that has been shown to be effective in the treatment of metastatic gastric and colorectal cancer patients. On the basis of capecitabine-based chemotherapy which is accepted as a standard regimen in gastric cancer, we will perform the phase I/II study with all-oral regimen of RAD001 with capecitabine for these refractory gastric cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus (RAD001) | dose escalation of capecitabine, everolimus |
| DRUG | Capecitabine | dose escalation of capecitabine, everolimus |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2013-08-01
- Completion
- 2013-12-01
- First posted
- 2010-04-07
- Last updated
- 2015-12-29
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01099527. Inclusion in this directory is not an endorsement.